Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr;14(6):e01177.
doi: 10.1213/XAA.0000000000001177.

Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report

Ryan T Nierstedt  1   2 , Rubaya Yeahia  2   3 , Kara M Barnett  2
Affiliations
Case Reports

Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report

Ryan T Nierstedt et al. A A Pract. 2020 Apr.

Abstract

We report a case of fatal immune checkpoint inhibitor (ICI)-associated myocarditis in a 77-year-old man with metastatic non-small cell lung cancer (NSCLC) who presented for mediport placement at our outpatient surgical center. He denied any cardiac complaints and had a previously normal electrocardiogram (EKG) off treatment. Intraoperatively and postoperatively, he displayed cardiac rhythm abnormalities. The patient was then transferred to a tertiary facility, where he expired within 48 hours. As cancer immunotherapy becomes increasingly prominent, ICI-associated myocarditis should be considered a potentially critical contributor to perioperative cardiac morbidity and mortality.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None

Figures

Figure 1.
Figure 1.
Preoperative electrocardiogram (EKG) from 3 months prior displaying normal sinus rhythm
Figure 2.
Figure 2.
Post-anesthesia care unit (PACU) EKG displaying fusion beats and intermittent right bundle branch block
See this image and copyright information in PMC

References

    1. Cho JH. Immunotherapy for non-small-cell lung cancer: Current status and future obstacles. Immune Netw 2017. 17(6):378–391. doi:10.4110/in.2017.17.6.378 - DOI - PMC - PubMed
    1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell. 2015. 161(2):205–14. doi:10.1016/j.cell.2015.03.030 - DOI - PMC - PubMed
    1. Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol 2018. 48(1):7–12. doi:10.1093/jjco/hyx154 - DOI - PubMed
    1. Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Oncologist. 2018. 23(8):874–878. doi:10.1634/theoncologist.2018-0157 - DOI - PMC - PubMed
    1. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med 2016. 14:73. doi:10.1186/s12916-016-0623-5 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances